Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tg Therapeuticscmn (NQ: TGTX )

13.45 +0.13 (+0.98%)
Streaming Delayed Price Updated: 11:16 AM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tg Therapeuticscmn

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why JAKKS Pacific Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Barnes & Noble Education, Inc. (NYSE: BNED) jumped 39% to $2.39 after the company posted better-than-expected quarterly sales. 
Via Benzinga
Where TG Therapeutics Stands With Analysts
Via Benzinga
Top 5 Health Care Stocks That May Collapse In February
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Here's How Much $100 Invested In TG Therapeutics 10 Years Ago Would Be Worth Today
Via Benzinga
The Latest Analyst Ratings for TG Therapeutics
Via Benzinga
Here's How Much $1000 Invested In TG Therapeutics 10 Years Ago Would Be Worth Today
Via Benzinga
'A Class Action Lawsuit Against TG Therapeutics Has Been Dismissed'
https://www.docdroid.com/05I9eLb/tg-therapeutics-class-action-dismissal-pdf https://twitter.com/TradeHawk/status/1613997810348879874 
Via Benzinga
Earnings Scheduled For February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
Why TG Therapeutics Stock Was a Solid Winner This Week
The company scored a giant victory on the regulatory front. 
Via The Motley Fool
Analyst Ratings for TG Therapeutics
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for TG Therapeutics: Here's What You Need To Know
Via Benzinga
B of A Securities Maintains Underperform Rating for TG Therapeutics: Here's What You Need To Know
Via Benzinga
Cramer Likens This Stock To 'A Fine Merlot': It's Down 1% In 2023, So 'I Would Buy All You Can Right Here'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Parker-Hannifin Corp (NYSE: PH) is "just the kind of industrial I’ve been recommending." 
Via Benzinga
TG Therapeutics Stock 300% Rally Has Legs Yet
There's further upside in the region of 30% yet to be realized, which should be more than enough to get even the more risk averse investor interested. 
Via MarketBeat
Exposures COVID-19 Product Safety
EXCLUSIVE: Top 10 Searched Tickers On Benzinga Pro In December 2022: Where Do Tesla, Apple, AMC Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
TG Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket
Gainers 
Via Benzinga
Ardelyx To Rally 160%? Here Are 10 Other Price Target Changes For Friday
Citigroup raised Ardelyx, Inc. (NASDAQ: ARDX) price target from $6 to $7. Citigroup analyst Yigal Nochomovitz maintained a Buy rating on the stock. Ardelyx shares rose 9.4% to $2.7685 on Friday. 
Via Benzinga
Shaw Communications, Enovix And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Now That FDA Approved TG Therapeutics Multiple Sclerosis Treatment, Analyst Are Boosting Price Targets
Wednesday, the FDA approved TG Therapeutics Inc's (NASDAQ: TGTX) Briumvi (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS). 
Via Benzinga
Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session
Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001. 
Via Benzinga
What's Going On With TG Therapeutics Shares
TG Therapeutics Inc (NASDAQ: TGTX) shares are trading higher by 9.34% to $9.25 Thursday morning. The company on Wednesday revealed FDA approval of ublituximab. What's Happening? 
Via Benzinga
Tesla To $250? Here Are 10 Other Price Target Changes For Thursday
Morgan Stanley cut Tesla, Inc. (NASDAQ: TSLA) price target from $330 to $250. Morgan Stanley analyst Adam Jonas maintained an Overweight rating on the stock. Tesla shares rose 4.4% to $117.65 in... 
Via Benzinga
Tesla, Hyzon Motors And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Why Cal-Maine Foods Shares Are Trading Lower; Here Are 24 Stocks Moving Premarket
Gainers Quotient Limited (NASDAQ: QTNT) shares rose 125% to $0.54 in pre-market trading after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the... 
Via Benzinga
Pfizer Makes Progress, but This Biotech Was Wednesday's Big Winner
The stock market lost ground as economic worries persist. 
Via The Motley Fool
Here's Why TG Therapeutics (TGTX) Shares Are Skyrocketing
TG Therapeutics Inc (NASDAQ: TGTX) shares are trading higher by 8.82% to $8.51 Wednesday afternoon following FDA approval of ublituximab. What's Happening? 
Via Benzinga
Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
Gainers Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal... 
Via Benzinga
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. 
Via Benzinga
Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session
Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.